Showing 241-250 of 830 results for "".
- Galderma Partners with AARS in Support of CDC's "Get Smart About Antibiotics Week"https://practicaldermatology.com/news/20141121-galderma_partners_with_aars_in_support_of_cdcs_get_smart_about_antibiotics_week/2459055/Galderma Laboratories, L.P. joined the American Acne and Rosacea Society (AARS) and the Centers for Disease Control and Prevention's (CDC) Get Smart About Antibiotics Week 2014 (November 17 – 23). AARS and Galderma Laboratories, the first dermatology partner to join with AARS on the initiative, are
- Allergan Comments on Pershing Square's and Valeant's Attempt to Remove a Majority of the Members of the Allergan Board of Directorshttps://practicaldermatology.com/news/20140602-allergan_comments_on_pershing_squares_and_valeants_attempt_to_remove_a_majority_of_the_members_of_the_allergan_board_of_directors/2459220/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today issued the following statement regarding the filing by Pershing Square Capital Management, L.P. ("Pershing Square") of preliminary proxy materials with the Securities and Exchange Commission ("SEC") in order to solicit proxies to call a
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Ac
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
2019 In Review
https://practicaldermatology.com/topics/practice-management/2019-in-review/23168/A look back at approvals, data, and industry developments of the year.SCALE 2024: Dr. Joel Cohen Interviews Dr. Saranya Wyles on Exosomes
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-joel-cohen-interviews-dr-saranya-wyles-exosomes/26364/Saranya Wyles, MD, PhD, joins Joel Cohen, MD, to discuss her research on exosomes at Music City SCALE.SCALE 2024: Listen as Dr. Joel Cohen and Dr. Suneel Chilukuri on Microwave Therapy
https://practicaldermatology.com/error/404/Suneel Chilukuri, MD, discusses the various applications of microwave therapy, including non-melanoma skin cancer, with Joel Cohen, MD, at Music City SCALE.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. James Q. Del Rosso on Innovative Therapies
https://practicaldermatology.com/error/404/James Q. Del Rosso, DO, joins Joel Cohen, MD, to discuss innovation in the world of acne and rosacea, atopic dermatitis, psoriasis, alopecia areata, hidradenitis suppurativa, vitiligo, and more at Music City SCALE.Dr. Joel Schlessinger's Tips for Hiring
https://practicaldermatology.com/topics/practice-management/dr-joel-schlessinger-39-s-tips-for-hiring/19295/In this video, Dr. Joel Schlessinger offers his advice for hiring employees. When finding new staff for his own practice, Dr. Joel Schlessinger makes sure each employee is a great fit for his organization. He puts each candidate through a test to find out if he or she is detail oriented, makes a poi